Skip to main content
Disc Medicine, Inc. logo

Disc Medicine, Inc. — Investor Relations & Filings

Ticker · IRON ISIN · US36870G1058 US Manufacturing
Open in API
Filings indexed 690 across all filing types
Latest filing 2023-06-20 Major Shareholding Noti…
Country US United States of America
Listing US IRON

About Disc Medicine, Inc.

https://www.discmedicine.com/

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients with serious hematologic diseases. The company's research focuses on fundamental pathways of red blood cell biology to address a range of disorders. Its pipeline includes bitopertin, an investigational therapy for erythropoietic protoporphyria (EPP) for which a New Drug Application has been submitted for accelerated approval. Other clinical-stage programs are evaluating treatments for myelofibrosis-associated anemia and other conditions involving ineffective erythropoiesis.

Recent filings

Filing Released Lang Actions
SC 13D/A
Major Shareholding Notification
2023-06-20 English
FORM 4 SUBMISSION
Director's Dealing
2023-06-20 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to a public offering of common stock and pre-funded warrants, including underwriting details, pricing, and expected proceeds. It also references press releases announcing the offering and pricing. There are no financial statements or detailed financial performance data included, only an announcement of a financing transaction. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is over 10,000 characters, indicating it is a full filing rather than a brief announcement. Therefore, the appropriate classification is CAP with high confidence.
2023-06-16 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement and accompanying prospectus filed pursuant to Rule 424(b)(5) related to a public offering of common stock and pre-funded warrants. It includes detailed offering terms, underwriting information, risk factors, use of proceeds, and legal matters. This type of document is a capital raising disclosure, specifically a prospectus supplement for a securities offering. It is not an annual report, earnings release, or any other financial report type. It is a detailed disclosure related to financing activities and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not RPA or RNS. Confidence is high given the clear nature of the document as a prospectus supplement for a securities offering.
2023-06-15 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content describes the suspension of a proposed registered underwritten public offering and details about the sales agreement and shares sold. It does not contain financial statements or detailed financial analysis, nor is it an earnings release or annual/interim report. The document is an update on capital raising activities, specifically about the suspension of a share offering. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 6004 characters, which is sufficient for a substantive announcement. No other category fits better given the content and form type.
2023-06-12 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement and accompanying prospectus related to an offering of common stock and pre-funded warrants. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and legal matters. The document is filed pursuant to Rule 424(b)(5), which is a SEC rule for prospectus supplements related to securities offerings. The content focuses on capital raising activities and securities issuance rather than financial results, management changes, or regulatory filings unrelated to financing. Therefore, this document is best classified as a Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement but a full offering document, supporting high confidence in this classification.
2023-06-12 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.